Evidence map›Paper›PMID 35514994›Full record

ArticleFrontiers in immunology2022

Defining Discriminatory Antibody Fingerprints in Active and Latent Tuberculosis.

Nadege Nziza, Deniz Cizmeci, Leela Davies, Edward B Irvine, Wonyeong Jung, Brooke A Fenderson, Marwou de Kock, Willem A Hanekom, Kees L M C Franken, Cheryl L Day and 2 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 30 citations in OpenAlex.

  1. Tuberculosis treatment and cytotoxic immune signatures: a longitudinal study.Journal of clinical tuberculosis and other mycobacterial diseases · 2026
    Article
  2. Review
  3. A proteome-wide atlas of humoral immunity toFrontiers in immunology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Maternal HIV infection drives altered placentalFrontiers in microbiology · 2023
    Article
  19. Article
  20. Antibodies as clinical tools for tuberculosis.Frontiers in immunology · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Nadege NzizaRagon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States.
Deniz CizmeciRagon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States.
Leela DaviesRagon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States.
Edward B IrvineRagon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States.
Wonyeong JungRagon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States.
Brooke A FendersonRagon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States.
Marwou de KockSouth African Tuberculosis Vaccine Initiative (SATVI) and School of Child and Adolescent Health, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Willem A HanekomAfrica Health Research Institute, Durban, South Africa.
Kees L M C FrankenDepartment of Infectious Disease, Leiden University, Leiden, Netherlands.
Cheryl L DayDepartment of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA, United States.
Tom H M OttenhoffDepartment of Infectious Disease, Leiden University, Leiden, Netherlands.
Galit AlterRagon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States.
Ragon Institute of MGH, MIT and Harvard · USLeiden University · NLBrigham and Women's Hospital · USEmory University · USUniversity College London · GBUniversity of Cape Town · ZA

Funding

Emory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Neel Rajnikant Gandhi, Jyothi Rengarajan · 2022 to 2026
$5.8M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
Mapping and dissecting the role of antibodies in Mtb controlR56AI155149 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2020 to 2020
$815k
NIAID NIH HHS P30 AI168386NIAID NIH HHS R37 AI080289NIAID NIH HHS R56 AI155149
6 · The paper itself

Abstract

Tuberculosis (TB) is among the leading causes of death worldwide from a single infectious agent, second only to COVID-19 in 2020. TB is caused by infection with

Indexed as

COVID-19HIV InfectionsLatent TuberculosisTuberculosisAntibodiesHumansAntibodiesactive and latent tuberculosisantibodiesbiomarkersdiagnosticsHIV

Identifiers

PMID35514994
PMCPMC9066635
OpenAlexW4224286192

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.